This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0356

Prevalence of substance use disorders in people with spinal cord injury: a systematic review

PREVALENCE OF SUBSTANCE USE DISORDER IN PEOPLE WITH SPINAL CORD INJURY: A SYSTEMATIC REVIEW

Rates of problematic opioid, cannabis, alcohol, and gabapentinoid use are markedly higher in people with spinal cord injury than in the general population.

This review aimed to synthesize the prevalence of substance use, misuse, and substance use disorders (SUDs) among individuals with spinal cord injury (SCI) across different substances and diagnostic criteria. PubMed was searched using the MeSH terms 'Spinal Cord Injuries' and 'Substance-Related Disorders', with the search limited to the past 10 years; 36 records were screened, 14 full-text articles were assessed, and 12 studies met the eligibility criteria. Risk of bias was assessed using ROBIS-E, and results were presented narratively and in descriptive tables. The 12 included studies involved more than 35,000 participants and predominantly used observational designs based on large databases; nearly all were conducted in the United States, with one conducted in Türkiye. The prevalence of opioid-related SUD ranged from 1.7% to 26%, while chronic opioid use reached 29.7%; compared with the general population, SCI was associated with higher odds of opioid use disorder (odds ratio, OR 7.97) and cannabis use disorder (OR 7.83). Alcohol abuse was estimated at 57% and alcohol dependence at 25%; post-injury cannabis use was reported at between 28.8% and 53%; gabapentinoid misuse reached 81.9% among those with neuropathic pain, and the risk of pain medication misuse was found to be 17.6%. Highlighting heterogeneity in diagnostic criteria and prescription-based and self-reported measures, the authors emphasize the need for systematic screening and integrated management of pain and mental health in this population.

All WCP 2026 summaries